Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRTX NASDAQ:IRWD NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.31+6.5%$0.97$0.74▼$2.48$232.03M1.72.15 million shs4.62 million shsIRWDIronwood Pharmaceuticals$4.83+3.4%$3.69$0.53▼$5.78$761.48M0.291.91 million shs3.76 million shsLGNDLigand Pharmaceuticals$232.55+0.1%$211.74$98.89▼$247.38$4.65B1.2220,161 shs185,392 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics+6.50%+10.08%+61.63%+8.26%-45.87%IRWDIronwood Pharmaceuticals+3.43%+16.39%+36.83%+8.54%+421.09%LGNDLigand Pharmaceuticals+0.11%+3.42%+14.21%+21.32%+125.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.31+6.5%$0.97$0.74▼$2.48$232.03M1.72.15 million shs4.62 million shsIRWDIronwood Pharmaceuticals$4.83+3.4%$3.69$0.53▼$5.78$761.48M0.291.91 million shs3.76 million shsLGNDLigand Pharmaceuticals$232.55+0.1%$211.74$98.89▼$247.38$4.65B1.2220,161 shs185,392 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics+6.50%+10.08%+61.63%+8.26%-45.87%IRWDIronwood Pharmaceuticals+3.43%+16.39%+36.83%+8.54%+421.09%LGNDLigand Pharmaceuticals+0.11%+3.42%+14.21%+21.32%+125.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRTXHeron Therapeutics 2.20Hold$4.50243.51% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2329.05% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$256.2910.21% UpsideCurrent Analyst Ratings BreakdownLatest LGND, IRWD, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.004/28/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $252.004/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$276.00 ➝ $282.004/14/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$239.00 ➝ $243.003/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/24/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $276.003/11/2026LGNDLigand Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$244.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRTXHeron Therapeutics$154.90M1.60N/AN/A$0.07 per share18.71IRWDIronwood Pharmaceuticals$296.15M2.66$0.27 per share18.14($1.61) per share-3.00LGNDLigand Pharmaceuticals$268.09M17.38$7.86 per share29.58$51.68 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRTXHeron Therapeutics-$20.19M-$0.13N/A10.92N/A-13.04%N/A-4.62%5/11/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.1337.15N/AN/A8.11%-13.72%10.95%5/7/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$5.8339.8931.511.6846.42%13.86%10.18%5/6/2026 (Estimated)Latest LGND, IRWD, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84N/AN/AN/A$59.10 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03N/AN/AN/A$36.72 millionN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.24N/AN/AN/A$92.11 millionN/A2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 million2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 million2/25/2026Q4 2025IRWDIronwood Pharmaceuticals$0.02-$0.01-$0.03-$0.01$86.10 million$47.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRTXHeron Therapeutics10.592.481.51IRWDIronwood PharmaceuticalsN/A1.131.13LGNDLigand Pharmaceuticals0.4422.2321.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRTXHeron Therapeutics80.01%IRWDIronwood PharmaceuticalsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipHRTXHeron Therapeutics5.86%IRWDIronwood Pharmaceuticals12.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million142.35 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableLGND, IRWD, and HRTX HeadlinesRecent News About These CompaniesOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced ...May 6 at 1:20 PM | caledonianrecord.comCLigand to Participate in May Investor ConferencesMay 5 at 4:01 PM | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 SharesMay 5 at 4:19 AM | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of StockMay 4 at 8:47 PM | marketbeat.comBank of America Securities Keeps Their Buy Rating on Ligand Pharma (LGND)May 2, 2026 | theglobeandmail.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KSMay 2, 2026 | marketbeat.comHC Wainwright Brokers Increase Earnings Estimates for LGNDMay 1, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $289.00 Price Target at HC WainwrightMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceApril 30, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - Here's WhyApril 29, 2026 | marketbeat.comMoody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGNDApril 29, 2026 | marketbeat.comRoyal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceApril 28, 2026 | marketbeat.comLigand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS OutlookApril 27, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - SlideshowApril 27, 2026 | seekingalpha.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationApril 27, 2026 | prnewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - Still a Buy?April 27, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings GuidanceApril 27, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) M&A Call TranscriptApril 27, 2026 | seekingalpha.comLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, IRWD, and HRTX Company DescriptionsHeron Therapeutics NASDAQ:HRTX$1.31 +0.08 (+6.50%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.38%) As of 05/6/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Ironwood Pharmaceuticals NASDAQ:IRWD$4.83 +0.16 (+3.43%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$4.85 +0.02 (+0.48%) As of 05/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Ligand Pharmaceuticals NASDAQ:LGND$232.55 +0.25 (+0.11%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$232.17 -0.38 (-0.16%) As of 05/6/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
